Addendum
PFS was examining time to progression of any metastatic tumour i.e within liver and/or outside.
If 40% of subjects had tumours outside the liver, at the time any of those increased in size (on CT scan) they are deemed to have had a progression.
But why wouldn't the tumours outside the liver continue to grow at the same rate? Those tumours got the same chemo but weren't exposed to the Sirspheres?
If, and this is only if, the overall survival figures for the sirspheres patients were better because the liver tumours were smaller, then this trial report has caused some shareholders who sold some significant damage. And it is still entirely possible that OS is better without any benefit in PFS outside the liver.
- Forums
- ASX - By Stock
- SRX
- CAFA on Sirtex
CAFA on Sirtex, page-5
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SRX (ASX) to my watchlist
|
|||||
Last
17.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $74.27M |
Open | High | Low | Value | Volume |
17.5¢ | 17.5¢ | 17.5¢ | $19.81K | 113.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
13 | 6422505 | 17.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
18.0¢ | 1547308 | 16 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
13 | 6422505 | 0.175 |
4 | 1072000 | 0.170 |
1 | 18186 | 0.165 |
3 | 119000 | 0.160 |
1 | 387096 | 0.155 |
Price($) | Vol. | No. |
---|---|---|
0.180 | 1547308 | 16 |
0.185 | 96569 | 3 |
0.190 | 87847 | 4 |
0.195 | 500000 | 1 |
0.200 | 451244 | 10 |
Last trade - 15.58pm 30/07/2024 (20 minute delay) ? |
Featured News
SRX (ASX) Chart |
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online